Sibeprenlimab
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Sibeprenlimab (Voyxact) for primary immunoglobulin A nephropathy.
Journal: The Medical letter on drugs and therapeutics
Published: July 24, 2026
Efficacy and safety of BAFF/APRIL-pathway inhibitors versus placebo in adults with IgA nephropathy: a systematic review with pairwise and network meta-analysis.
Journal: BMC nephrology
Published: July 08, 2026
Efficacy and safety of sibeprenlimab in IgA nephropathy: interim analysis of the China cohort in the phase 3 VISIONARY trial.
Journal: Clinical kidney journal
Published: April 01, 2026
Efficacy and safety of sibeprenlimab in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.
Journal: BMC nephrology
Published: January 27, 2026
Humoral Response to COVID-19 Vaccines and Infection during Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION Trial.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: December 22, 2025
Emerging Therapies in IgA Nephropathy: From A Proliferation-Inducing Ligand (APRIL) and B-cell Activating Factor (BAFF) Inhibitors to Precision Medicine.
Journal: Cureus
Published: December 21, 2025
Reshaping the therapeutic landscape of IgA nephropathy: a Bayesian network meta-analysis on the comparative efficacy and safety of immunosuppressants and targeted agents.
Journal: BMC nephrology
Published: December 19, 2025
Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
Journal: The New England journal of medicine
Published: November 10, 2025
Approved therapies in the IgA nephropathy armamentarium: a summary of the evidence.
Journal: Kidney international supplements
Published: July 29, 2025
Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial.
Journal: Kidney international reports
Published: June 06, 2025
Last Updated: 09/26/2026